Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
Journal
Cancer medicine
Date Issued
2022-03-29
Author(s)
Abstract
Front-line platinum-base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front-line regimens: cisplatin, doxorubicin, and cyclophosphamide (CAP); cisplatin and etoposide (EP); or cisplatin and paclitaxel (TP).
Subjects
front-line chemotherapy; overall survival; thymic carcinoma; thymoma
SDGs
Publisher
WILEY
Type
journal article